SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0725+3.6%Oct 31 3:52 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pincus who wrote (12964)6/18/2014 5:33:24 PM
From: Howard Williams  Read Replies (1) of 13111
 
Favorable interim Phase 3 results could come well before the end of 2015 given that DTIC and TMZ have PFS values of 1.5 and 1.9 months, respectively. So, as Alan Ross says, "We know that the direct cancer-killing effect of PV-10 is very fast. Moffitt Cancer Center research showed that cancer cells were no long viable when biopsies were taken 7 or 14 days after initial treatment. The prompt efficacy of PV-10 could lead to obvious differences in disease progression, symptoms, significant side effects, and even the extent of deaths between PV-10 and Chemo groups of patients long before the planned 15 month Interim Assessment is due."

As far as "hunkering down" goes, that suggestion appears to ignore other potential developments involving PV-10 and PH-10, including MOAs, foreign licenses, other indications, etc.

Hopefully Thursday's conference call will clear up the picture.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News